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7610 | Chem. Sci., 2019, 10, 7610–7618l membrane binding proteins to
direct stem cells to the myocardium†
Wenjin Xiao,‡a Thomas I. P. Green,‡ab Xiaowen Liang,‡c Rosalia Cuahtecontzi Delint,ab
Guillaume Perry, d Michael S. Roberts,ce Kristian Le Vay,ab Catherine R. Back,fg
Raimomdo Ascione,h Haolu Wang,c Paul R. Racefg and Adam W. Perriman*ag
We present a new cell membrane modiﬁcation methodology where the inherent heart tissue homing
properties of the infectious bacteria Streptococcus gordonii are transferred to human stem cells. This is
achieved via the rational design of a chimeric protein–polymer surfactant cell membrane binding
construct, comprising the cardiac ﬁbronectin (Fn) binding domain of the bacterial adhesin protein CshA
fused to a supercharged protein. Signiﬁcantly, the protein–polymer surfactant hybrid spontaneously
inserts into the plasma membrane of stem cells without cytotoxicity, instilling the cells with a high
aﬃnity for immobilized ﬁbronectin. Moreover, we show that this cell membrane reengineering approach
signiﬁcantly improves retention and homing of stem cells delivered either intracardially or intravenously
to the myocardium in a mouse model.Introduction
There has been signicant interest in the development of cell-
based therapies for the treatment of disease, due to the major
and increasing burden on health outcome and life expectancy.
However, challenges remain in relation to cellular delivery mode,
eﬃcacy, oﬀ-target eﬀects and therapeutic mechanism of action.
For example, studies using stem cells in vivo to regenerate
myocardium post ischemia have postulated many potential
mechanisms linked to cell type, including functional integration
with cardiomyocytes, paracrine eﬀects from secreted factors,
tissue matrix remodelling via metalloproteases, as well as
recruitment of monocytes and macrophages to repair micro-
vessels.1–3 For the majority of these mechanisms, it is clear that
the therapeutic cells need to be recruited/retained at the site of
injury in signicant numbers and for a suﬃcient duration to bene, University of Bristol, BS8 1TD, UK.
s, University of Bristol, BS8 1FD, UK
Institute, The University of Queensland,
abba, QLD 4102, Australia
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and Bristol Heart Institute, University of
tion (ESI) available. See DOI:
e work and are joint rst authors.able to have an eﬀect. Accordingly, increasing cell homing and
retention is likely to be advantageous, especially as myocardial
retention of cells delivered via intravenous (IV), intra-arterial (IA),
or intramyocardial (IM) injections are associated with only 0%
(IV), 2% (IA) and 10–15% (IM) retention up to 3 days post-
injection, followed by rapid signal loss over 24 hours.4–6
Such low levels of viable cell retention in the myocardium can
be rationalized by a number of factors, including a lack of adhe-
sion of the cells to the site of injury, poor targeting by selected
delivery mode, high turbulent hemodynamic ow, aggressive or
hypoxic environments, and presence of inammatory cyto-
kines.4,5,7 To combat these eﬀects, several cell immobilization
approaches for in vivo site-directed tissue repair have been
developed. Cells have been transplanted in so biocompatible
matrices for enhanced retention using gelatin,8 alginate9 and
decellularized extracellular matrix (ECM) hydrogels.10 Synthetic
matrices comprising cell-supporting scaﬀolds produced from
polyglycerol-sebacate (PGS)11 and poly(octamethylene maleate
(anhydride) citrate) (POMaC)12 have also been utilized for
implantation. Although these approaches provide the added
benet of high cell numbers, they generally require more invasive
surgical procedures when compared with direct cell injection,
while the carrier biomaterials may feature unmatched biome-
chanical properties when compared with the myocardium.13
Cell membrane re-engineering is emerging as a powerful
new approach for in vivo tissue repair, where exogenous mole-
cules are directly introduced to the plasma membrane to drive
active cell homing to the site of injury. These approaches
commonly involve direct covalent modications of the
membrane binding homing motifs, and include antibodies,14,15
selectin-binding peptides16 and polymers.17 Recent studies onThis journal is © The Royal Society of Chemistry 2019
Fig. 1 The artiﬁcial plasma membrane binding construct. (a) Sche-
matic showing the interaction of the polymer surfactant conjugated
supercharged fusion [CshA_scGFP][S] construct with the bilayer of the
cytoplasmic membrane. The structure shows the surface charge
potential, highlighting the high positive charge (blue) on the super-
charged GFP domain and the negative charge (red) on the CshA
globular domain, as well as the “catch” and “clamp” domains of CshA.
(b) The structure of the anionic polymer surfactant glycolic acid
ethoxylate 4-nonylphenyl ether (S), which electrostatically complexes
with the supercharged GFP moiety.
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View Article Onlineincreasing homing of therapeutic cells18,19 and vesicles20,21 for
heart repair have achieved signicant improvement in
outcomes with reduced brosis and scar size, and increased
cellular proliferation and angiogenesis. However, these
approaches have drawbacks, including steric hindrance of the
homing paratope, non-organ specicity and oﬀ-target stimula-
tion of irrelevant sites.22 Accordingly, the conceptual advance
described herein is centred on utilising the inherent homing
properties of infectious bacteria by immobilizing the cardiac
bronectin (Fn) binding domain of the bacterial adhesin
protein CshA on the plasmamembrane of therapeutic cells. The
adherence of bacteria to biotic or abiotic surfaces is essential for
host colonization, persistence, and pathogenicity, and the
process is facilitated by bacterial adhesins, which recognize and
bind specic partner molecules presented on the surfaces of
host cells and other microorganisms.23 Fibronectin, a large and
essential multidomain glycoprotein, functioning as a key link
between cells and their extracellular matrices, has been recog-
nized as the target for a large number of bacterial adhesins.24
Signicantly, the CshA-Fn interaction directs S. gordonii to
damaged brotic regions of the cardiac endothelium, e.g.,
infarcted or scarred tissue, damaged or prosthetic heart valves,
promoting the onset of infective endocarditis,25–27 and undam-
aged cardiac Fn. Although Fn is expressed in healthy cardiac
tissue, expression levels are increased enormously aer
myocardial infarction.27,28 Here, the mechanism underpinning
the high levels of selectivity exhibited by CshA for cardiac Fn
involves an atypical “catch–clamp” process.29 Aer entering the
blood stream, the cell wall-bound adhesin rapidly samples the
localised ECM environment using an extended intrinsically
disordered low aﬃnity binding site (catch), which, upon
binding, activates a second high aﬃnity (clamp) to anchor the
bacterium to the immobilized Fn (Fig. 1a).
The ability to readily display the CshA binding motif on the
membrane of therapeutic cells, which has been evolutionarily
optimized to recognize and bind Fn in the cardiac endothelium
with high aﬃnity, would provide a new direction for cell-based
myocardial therapy. Accordingly, a designer CshA chimera
construct was converted into an articial membrane binding
protein using a protein surface reengineering methodology
recently developed in our laboratories.30 Here, the CshA Fn-
binding domain was fused to a supercharged green uores-
cent protein (scGFP), which was then electrostatically conju-
gated to polymer surfactant molecules to produce a cytoplasmic
membrane active polymer surfactant corona. Signicantly, this
new articial membrane binding construct was not cytotoxic,
spontaneously inserted into the plasma membrane of human
mesenchymal stem cells (hMSCs), did not elicit a hematologic
response in mice, and directed hMSCs, delivered either intra-
cardially or intravenously, to the mouse myocardium.
Results and discussion
Synthesis and characterisation of the protein–polymer
surfactant construct
The gene comprising the non-repetitive domains (NR1, NR2,
and NR3) of CshA (Fig. S1A†) fused to a +36 scGFP wasThis journal is © The Royal Society of Chemistry 2019synthesized (Table S1†), and the chimera CshA_scGFP (Fig. 1a)
was expressed in E. coli and puried using immobilized metal
aﬃnity chromatography (IMAC) and size exclusion chroma-
tography (SEC) (Fig. S1B†). Matrix-assisted laser desorption/
ionization time-of-ight (MALDI-TOF) mass spectrometry gave
a molecular weight of 112.6 kDa (Fig. S1C†), which conrmed
the presence of the intact CshA_scGFP construct. Electrostati-
cally driven conjugation between the cationic residue side-
chains and the anionic polymer surfactant glycolic acid
ethoxylate 4-nonylphenyl ether ([S], Fig. 1b) was performed over
a range of protein cationic sites : polymer surfactant ratios
(PCS : PS; 1 : 1.4, 1 : 2.1 and 1 : 2.8), followed by dialysis. UV-vis
spectra from the resulting dialysed constructs (Fig. S2A†)
showed strong absorbances arising from the scGFP uorophore
(487 nm) and the aromatic groups of both the protein and the
nonylphenyl moiety of the surfactant (270–280 nm). The protein
and polymer surfactant molar extinction coeﬃcients were used
to evaluate the nal PCS : PSs, which were 1 : 0.6, 1 : 1.1 and
1 : 1.6, indicating the removal of unbound surfactant molecules
during dialysis. Sedimentation velocity analyticalChem. Sci., 2019, 10, 7610–7618 | 7611
Fig. 2 The structure and conformation of the artiﬁcial membrane binding construct. Sedimentation velocity analytical ultracentrifugation (SV-
AUC) sedimentation coeﬃcient {c(s)} distributions at (a) 487 nm and (b) 280 nm. The distributions show the overlay of the surfactant [S] (black
dashed line), CshA_scGFP (black line) and [CshA_scGFP][S] at protein cationic sites : polymer surfactant ratios of 0.6 : 1 (red line), 1.1 : 1 (blue line)
and 1.6 : 1 (green line). (c) Synchrotron radiation small angle X-ray scattering (SR-SAXS) data from CshA_scGFP (black symbols) and
[CshA_scGFP][S] (red symbols) at 25 C. The corresponding P(r) distribution ﬁts (solid lines) were obtained using Bayesapp. (d) Pair-distance
distribution functions (P(r)) derived from SR-SAXS of CshA_scGFP (black trace) and [CshA_scGFP][S] (red trace). (e) Small angle neutron scattering
(SANS) data (symbols) with P(r) distribution ﬁts (solid lines) obtained using Bayesapp. SANS was used to probe the structure of CshA_scGFP in
100% D2O (black) and [CshA_scGFP][S] in 40% D2O (red) at 25 C. (f) Pair-distance distribution functions (P(r)) derived from SANS data ﬁtting of
CshA_scGFP in 100% D2O (black trace) and [CshA_scGFP][S] in 40% D2O (red trace).
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View Article Onlineultracentrifugation (SV-AUC) experiments were performed on
the three formulations at 487 nm and 280 nm to monitor the
chimera and the polymer surfactant independently. Signi-
cantly, electrostatic surfactant conjugation of CshA_scGFP to
yield [CshA_scGFP][S] increased the sedimentation coeﬃcient
(Abs 487 nm) of the primary feature from 4.1 to 4.8 S at
a PCS : PS of 1 : 0.6 (Fig. 2a and Table S2†). Moreover,
increasing the PCS : PS to 1 : 1.1 or 1 : 1.6 did not increase the
sedimentation coeﬃcient of this feature, which indicated that
the surfactant binding sites on the CshA_scGFP fusion were
saturated. Indeed, the emergence of a feature at ca. 1.6 S at
a PCS : PS of 1 : 1.1 (Abs 280 nm), which increased in magni-
tude at 1 : 1.6, signied the presence of free surfactant (Fig. 2b
and Table S2†). Accordingly, a PCS : PS of 1 : 0.6 was used for all
subsequent experiments.
The formation of the sub-stoichiometric [CshA_scGFP][S]
complex (PCS : PS of 1 : 0.6) can be rationalized by the aniso-
tropic distribution of cationic surface charge on the
CshA_scGFP construct (Fig. 1a). Here, the scGFP membrane
binding region displays a high density of cationic surface
charge (+36 at pH 7.5), which would favour cooperative surfac-
tant binding through hydrophobic tail burial beneath the PEG-
rich regions on the protein surface.31 Conversely, the CshA7612 | Chem. Sci., 2019, 10, 7610–7618motif has a theoretical net charge of 30 at pH 7.5. This was
reected in the low zeta potential of the CshA_scGFP construct,
which was +0.9 mV at pH 7.5, and decreased to 15.2 mV aer
the positive surface charges were neutralized via electrostatic
surfactant conjugation. The formation of a compact polymer
surfactant corona was also supported by dynamic light scat-
tering (DLS) experiments, which showed a 2 nm increase in the
hydrodynamic diameter (Fig. S2B†), increasing from approxi-
mately 10 nm for CshA_scGFP to 12 nm for [CshA_scGFP][S].
To study the constructs in higher resolution, synchrotron
radiation small angle X-ray scattering (SR-SAXS) and neutron
scattering (SANS) experiments were performed. For the
CshA_scGFP fusion construct, tting the SAXS scattering
pattern (Fig. 2c) yielded a radius of gyration of 7.4 0.4 nm with
an axial ratio of 10.6  0.4 (Table S3†). Moreover, the resulting
pair-distance distribution function (P(r)) rapidly decayed to
a distance of approximately 18 nm before extending out to
a Dmax of 29 nm (Fig. 2d). This “long tail” in the P(r) function
and high axial ratio can be reconciled by the dynamic intrinsi-
cally disordered NR1 “catch” domain in CshA,29 and the corre-
sponding Porod exponent of 2.1 0.1 (Table S3†) conrmed the
high level of exibility. SAXS experiments performed on
[CshA_scGFP][S] (Fig. 2c) showed that polymer surfactantThis journal is © The Royal Society of Chemistry 2019
Fig. 3 The interaction of the constructs with the hMSC plasma membrane. (a) (3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) (MTS) assay showing the MSC viability (via the total metabolic activity) as a function of CshA_scGFP (black) or
[CshA_scGFP][S] (red) incubation concentration. The bars represent the mean average and the error bars represent the standard deviation
calculated using hMSCs from 3 diﬀerent patients (n ¼ 3). The groups were tested using a one-way ANOVA followed by a two-tailed equal
variance Student's t-test. A p-value of less than 0.05 and 0.01 considered signiﬁcant (*) and highly signiﬁcant (**), respectively, when compared
to the untreated cells. (b) hMSC proliferation after incubation for 15 minutes with either with 4 mM CshA_scGFP (black) or 4 mM [CshA_scGFP][S]
(red), and the untreated cell controls (white). The treated cells retained their proliferation capability for 14 days in culture, indicating CshA_scGFP
and [CshA_scGFP][S] had no long-term eﬀects on cell self-renewal. The statistical approach was the same as for (a). Live cell ﬂuorescence
wideﬁeld microscopy images showing the cell membrane aﬃnity of (c) CshA_scGFP (green) imaged immediately after 15 minutes incubation,
and (d) after a further 12 hours, which shows the result of signiﬁcant endocytosis. Analogous experiments performed after incubation with
[CshA_scGFP][S] (green) show persistence ﬂuorescence at the plasmamembrane when (e) imaged immediately after 15 minutes incubation, and
(f) after a further 12 hours. Cell nuclei were stained with a Hoechst dye (blue). Scale bar ¼ 100 mm.
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View Article Onlineconjugation resulted in a 2.4 nm increase in the radius of
gyration (cf. CshA_scGFP), which was accompanied by a reduc-
tion in the axial ratio (from 10.6 to 8.2  0.1, Table S3†) and an
increase in the exibility of the construct (Porod exponent of 1.8
 0.1; Table S3†). SANS data tting (Fig. 2e) also yielded
parameters that were consistent with a highly elongated struc-
ture for CshA_scGFP (Table S3†), with a radius of gyration of
6.1 nm, and a P(r) function with Dmax of ca. 25 nm (Fig. 2f).
Experiments performed on [CshA_scGFP][S] at the protein
contrast match point (40 : 60 D2O : H2O) gave a bimodal P(r)
function (Fig. 2f), which indicated that although the majority of
surfactant chains were associated with the scGFP moiety, some
electrostatic assembly had occurred near the CshA domain.
The eﬀect of surfactant electrostatic conjugation on protein
structure was also investigated using synchrotron radiation
circular dichroism (SRCD) and uorescence spectroscopies.
Deconvolution of the Far-UV SRCD spectrum from the
CshA_scGFP fusion (Fig. S2C†) gave a secondary structure
distribution that was representative of the constituent protein
components, with high levels of disordered structure from NR1
of CshA29 (48.6%), as well as beta structure from scGFP32
(21.2%) and alpha helical content from NR2 and NR3 of CshA29
(16.1%) (Fig. S2D†). Signicantly, surfactant conjugation toThis journal is © The Royal Society of Chemistry 2019yield [CshA_scGFP][S] produced a SRCD spectrum that could be
superimposed on that of the fusion protein (Fig. S2C†), signi-
fying that no major changes in the secondary structure distri-
bution had occurred (Fig. S2E†). The persistence of protein
structure aer polymer surfactant conjugation was also sup-
ported by uorescence spectroscopy measurements, which
showed that both CshA_scGFP and [CshA_scGFP][S] retained
the characteristic uorescent signature of scGFP,33 with an
excitation peak at 487 nm and a corresponding emission peak at
510 nm (Fig. S2F†).The interaction of the articial membrane binding construct
with hMSCs
The potential cytotoxicity of the CshA_scGFP fusion and the
[CshA_scGFP][S] conjugate was evaluated by performing cell
viability experiments using bone marrow-derived hMSCs. Here,
hMSCs could be incubated in either construct up to protein
concentrations as high as 12 mM, without signicant cell death
(Fig. 3a). Accordingly, an incubation concentration of 4 mM was
used for all subsequent experiments, and hMSCs incubated
with either CshA_scGFP or [CshA_scGFP][S] retained their
ability to undergo self-renewal over a two week period (Fig. 3b).Chem. Sci., 2019, 10, 7610–7618 | 7613
Fig. 4 Static and dynamic cell adhesion on immobilised ﬁbronectin
(Fn). (a) Static adhesion assay showing the hMSC adherence to
immobilised Fn after cells were incubated for 15 minutes with 4 mM of
either CshA_scGFP (black) or [CshA_scGFP][S] (red), respectively, and
compared with untreated cell controls (white). Dynamic ﬂuidic
adhesion assay showing the hMSCs adherence to Fn at shear stress of
(b) 1 and (c) 1.5 dyne cm2, respectively. The bars represent the mean
and the error bars represent the standard deviation calculated using
hMSCs from 3 diﬀerent patients (n ¼ 3). Comparison of diﬀerences
was tested using one-way ANOVA followed by a two-tailed, equal
variance Student's t-test with a p-value of less than 0.05 and 0.01
considered signiﬁcant (*) and highly signiﬁcant (**), respectively,
compared to the untreated cells on either BSA or Fn coating.
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View Article OnlineSignicantly, live cell wideeld microscopy experiments showed
rapid labelling of the plasma membrane of the hMSCs aer
incubation with either CshA_scGFP or [CshA_scGFP][S] (Fig. 3c7614 | Chem. Sci., 2019, 10, 7610–7618and d). scGFP_CshA was also capable of labelling hMSCs in
a mechanism mediated by electrostatic attraction to anionic
sulphated proteoglycans on the plasma membrane, which is
consistent with studies of supercharged proteins.30,32,33 More-
over, supernatant depletion assays performed on the constructs
aer incubation with the hMSCs showed approximately 2
billion and 0.7 billion constructs per cell for CshA_scGFP and
[CshA_scGFP][S], respectively (Fig. S4A†). Fluorescence acti-
vated ow cytometry measurements showed complete labelling
of the hMSCs populations by both constructs, with no signi-
cant diﬀerence in the total uorescence intensity between the
samples (Fig. S4B†). As the ow cytometry assays could not
discriminate between constructs on the plasmamembrane or in
the cytosol, time course live-cell wideeld uorescence
microscopy experiments were conducted, which showed that
the [CshA_scGFP][S] persisted at the plasma membrane for at
least 12 hours (Fig. 3f). Conversely, the CshA_scGFP was rapidly
endocytosed over the same period (Fig. 3e), which is consistent
with a recent report by Krishnan et al.34 that described a strong
cationic surface charge dependency for tissue and cell uptake of
supercharged green uorescent proteins. The cardiogenic
diﬀerentiation potency of hMSCs aer the [CshA_scGFP][S]
modication was also investigated. Aer exposed to 5-azacyti-
dine, the [CshA_scGFP][S] modied hMSCs acquired phenotype
of cardiomyocytes as shown by the expression of cardiac
biomarkers including cardiac transcription factor Nkx2.5,
alpha-cardiac actin and cardiac troponin T (Fig. S5†).Modied hMSC bronectin adhesion assays
Following the demonstration of persistent and eﬃcient hMSC
membrane labelling, static adhesion assays were performed to
assess the ability of the modied cells to bind to immobilized
human bronectin (Fn). Here, hMSCs were seeded onto Fn-
coated substrates and bovine serum albumin (BSA) blocked
substrates were used as controls. Wideeld microscopy per-
formed on samples showed hMSCs rmly adhered to the Fn-
coated dishes aer 6 hours of incubation, with the typical at
broblastic morphology of hMSCs (Fig. S6†). Signicantly,
quantitative biochemical assays revealed that the cells labelled
with either construct exhibited an increase in adhesion, with
[CshA_scGFP][S] producing a two-fold increase in hMSC
adherence compared to untreated hMSCs (Fig. 4a). To explore
the process adhesion under dynamic conditions, a biomimetic
microuidic adhesion assay was performed to model interac-
tions between circulatingmodied hMSCs and immobilized Fn.
Here, the microuidic channel was coated with Fn and controls
blocked using BSA. By owing hMSCs at physiologically-
relevant shear stresses (1–5 dyne cm2 (ref. 35)), a general
trend was observed, whereby fewer cells adhered to Fn at higher
shear stresses (Movies S1, S2 and S3†). Signicantly,
CshA_scGFP and [CshA_scGFP][S] both conveyed signicantly
higher adherence of hMSCs to Fn at shear stresses of 1 and 1.5
dyne cm2 when compared to untreated hMSCs (Fig. 4b and c).
This conrmed that the Fn binding propensity of CshA could be
eﬀectively transferred from Streptococcus gordonii to human
stem cells in vitro.This journal is © The Royal Society of Chemistry 2019
Fig. 5 The eﬀect of the construct on hMSCs homing and retention in amurine heart. Representative laser scanning confocal microscopy images
fromDAPI (blue) stained 10 mm sections of murine heart after intracardiac injection of 2 000 000 untreated hMSCs or [CshA_scGFP][S]-modiﬁed
hMSCs. All hMSCs were stained with CMPTX cell tracker (red) before injection. (a) Control unmodiﬁed hMSCs after 2 hours, and (b) after 24 hours.
(c) [CshA_scGFP][S]-modiﬁed hMSCs after 2 hours, and (d) after 24 hours. (e) [CshA_scGFP][S]-modiﬁed hMSCs after 24 hours. High magniﬁ-
cation composite (brightﬁeld/ﬂuorescence) images show the presence of the [CshA_scGFP][S] construct (green) on the cells (red) after (e) 2
hours and (f) after 24 hours. Scale bar ¼ 200 mm.
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View Article OnlinehMSCs homing in vivo
In light of the positive Fn adhesion results, an in vivo mouse
model was used to assay the propensity of the [CshA_scGFP][S]
construct to promote stem cell homing to the myocardium. It
was hypothesised that as the bronectin sequence is remark-
ably well conserved among higher animals,24 that suﬃcient
targets for the CshA would still be present. Prior to the in vivo
administration of the modied hMSCs, the hemocompatibility
and systemic toxicity of the [CshA_scGFP][S] construct were
evaluated in mice. Signicantly, no granulocyte activation,
thrombocyte activation, or hemolysis was observed in whole
blood samples at 2 hours and 24 hours aer the intravenous
injection of [CshA_scGFP][S] (Table S4†). Accordingly,
[CshA_scGFP][S] modied hMSCs were intravenously trans-
planted into mice and the systemic toxic eﬀects were evaluated
by examining the pathological changes of the major organs
aer 4 weeks. No notable diﬀerences were observed in the heart,
lung, kidney or liver among these groups (Fig. S7†), suggesting
that [CshA_scGFP][S] modied hMSCs had no acute toxic eﬀects
on normal tissues in vivo. The CshA sequence is derived from
a commensal organism, which may help reduceThis journal is © The Royal Society of Chemistry 2019immunogenicity. Moreover, as the membrane functionalization
is transient (endocytosed by the transplanted cell), this may also
help to reduce immunogenicity. For future work, and eventual
clinical translation of this system, it will be essential to perform
reactivity assays on T- and B-cell proliferation from peripheral
human blood aer exposure to the chimera-polymer surfactant
conjugates as well as complementary enzyme-linked immuno-
sorbent assays (ELISA).
The distribution of hMSCs and [CshA_scGFP][S] modied
hMSCs in mouse organs aer intracardiac injection (Movie S4†)
was explored at the cellular level using confocal microscopy,
where cells were labelled with red CMPTX cell tracker before
injection. Representative images of untreated hMSCs and
[CshA_scGFP][S] modied hMSCs in frozen heart sections at 2
and 24 hours aer the intracardiac injection showed that the
[CshA_scGFP][S] modied hMSCs retained their uorescence
for 24 hours in vivo and could be readily distinguished against
the tissue background (Fig. 5a–f). Quantitative PCR assays for
human-specic Alu sequences36 were performed to evaluate the
number of [CshA_scGFP][S] modied hMSCs and control
hMSCs at 2 hours and 24 hours aer either intracardiac or
intravenous injection. Signicantly, an in vivo cytokineticChem. Sci., 2019, 10, 7610–7618 | 7615
Fig. 6 In vivo kinetics of untreated hMSCs (black) and [CshA_scGFP][S] modiﬁed hMSCs (red) in the heart after (a) intracardiac or (b) intravenous
injection of 2  106 cells. The solid line represents the concentration–time proﬁle of the hMSCs simulated by the physiologically based kinetic
model while the closed triangles or squares represent measured biodistribution data. Concentration of untreated hMSCs (black) and
[CshA_scGFP][S] modiﬁed hMSCs (red) in the lung at 2 hour and 24 hour after (c) intracardiac and (d) intravenous injection. Concentration of cells
is expressed as number of cells per kilogram of tissue. The triangles and squares represent the mean average and the error bars represent the
standard deviation calculated using cells from 3 mice (n ¼ 3), and comparison of diﬀerences was tested using a two-tailed, unequal variance
Student's t-test with a p-value of less than 0.05 and 0.01 considered signiﬁcant (*) and highly signiﬁcant (**), respectively.
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View Article Onlinemodel37 was applied to the resulting data to elucidate the in vivo
spatiotemporal disposition of the administered hMSCs, which
showed that the tissue:plasma distribution coeﬃcient of hMSCs
in the heart had increased by 100% aer modication with
[CshA_scGFP][S] for both intracardiac and intravenous injec-
tion (Fig. 6a and b, Table S5†). Moreover, hMSC accumulation
in the lung did not diﬀer between untreated hMSCs and
[CshA_scGFP][S] modied cells (Fig. 6c and d), which indicated
that the process involved cell homing and not simply retention.Conclusions
In this work, we rationally designed, built and characterised
a protein chimera-polymer surfactant construct with cardiac
tissue homing properties, which spontaneously inserted into
the plasma membrane of hMSCs. Where this system diﬀers
considerably from non-homing approach is two-fold. Firstly, we
hijacked the innate ability of Streptococcus gordonii to home to
cardiac tissue by displaying an articial membrane binding
analogue of the bacterial adhesin CshA on the surface of
hMSCs. Bacterial adhesins exhibit exquisite selectivity for target
molecules and recognize molecular motifs in a lock-and-key
fashion, in line with enzymes and immunoglobulins.23
Accordingly, our approach could be readily extended to include7616 | Chem. Sci., 2019, 10, 7610–7618other adhesins that exhibit specic protein–protein interactions
to drive homing of therapeutic cells to diﬀerent organs, e.g.,
brain, kidney, liver, and related acute or chronic disease.
Secondly, we demonstrated that a supercharged protein motif
can be used to drive the electrostatic assembly of a cell
membrane active polymer surfactant corona. This hydrophobic
nonylphenyl chain membrane insertion mechanism presents
a number of key advantages. The process is facile, non-cytotoxic
and does not require genetic modications of the cells. More-
over, as our cell membrane engineering display system is
completely independent of the cell type, it could be readily
applied to other therapeutic cells, including endothelial
progenitor cells, bone marrow-derived mononuclear cells, and
pluripotent stem cells.38
In summary, we demonstrate a completely bacterial adhesin-
based homing technology with several key advantages, such as
ease of synthesis and handling of both the anchor region and
homingmolecule, large construct display number (billions) and
persistence (>12 hours) on the cell surface, no loss of the bio-
logical function of protein aer membrane insertion, and high
specicity for in vitro/in vivo aﬃnity to Fn. We show that the
construct is not cytotoxic, does not elicit a hematologic
response in mice, and directs engineered hMSCs delivered
either intracardially or intravenously to home selectively to theThis journal is © The Royal Society of Chemistry 2019
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View Article Onlinemyocardium, without a concomitant increase in the number of
cells in the lungs.Conﬂicts of interest
A. W. P. is the Founder, a Director and a shareholder of Cyto-
Seek, a company engaged in the development of cell membrane
reengineering. W. X., T. I. P. G. and R. C. D. are shareholders of
CytoSeek. Work in the Perriman laboratories at the University of
Bristol is supported in part by CytoSeek. The remaining authors
declare no competing interests.Acknowledgements
We would like to acknowledge the Wolfson Bioimaging Centre
(BBSRC Alert 13 capital grant BB/L014181/1) and the Flow
Cytometry Facility at the University of Bristol. We also would
like to acknowledge the Diamond Light Source (UK) for access
to Far-UV SRCD at beamline B23 and SAXS at beamline B21, as
well as the ILL (France) for SANS at beamline D22. We would
like to thank Dr D. Frankel for assisting with the microuidics,
Dr B. Carter for assisting with Fig. 1 and SANS, Dr W. Zhang for
assisting with the protein purication, G. Day for assisting with
the BCA assay, M. Doran for providing the hMSCs, S. Roy for
assisting with the imaging, and B. Tse for assisting with the in
vivo experiments. We thank EPSRC Doctoral Training Centre
Grant EP/G036780/1 for funding Dr T. I. P. G. and the EPSRC
(Early Career Fellowship EP/K026720/1), the UKRI (Early Career
Fellowship EP/K026720/1 and Future Leaders Fellowship MR/
S016430/1) for support for Dr A. W. P. This work was also sup-
ported by grants from the Australian National Health and
Medical Research Council (APP1126091, to M. S. R. and
APP1141121, to H. W.). The datasets corresponding to this
Manuscript and Supporting Information are available at DOI:
10.5523/bris.21w0xiagciryg2b1gcdaxn5z2q.References
1 M. Angelos and D. Kaufman, Curr. Opin. Organ Transplant.,
2015, 20, 663–670.
2 S. A. Fisher, C. Doree, A. Mathur and E. Martin-Rendon, Circ.
Res., 2015, 116, 1361–1377.
3 G. Condorelli, U. Borello, L. De Angelis, M. Latronico,
D. Sirabella, M. Coletta, R. Galli, G. Balconi, A. Follenzi,
G. Frati, M. G. Cusella De Angelis, L. Gioglio,
S. Amuchastegui, L. Adorini, L. Naldini, A. Vescovi,
E. Dejana and G. Cossu, Proc. Natl. Acad. Sci. U. S. A., 2001,
98, 10733–10738.
4 D. Hou, E. A. S. Youssef, T. J. Brinton, P. Zhang, P. Rogers,
E. T. Price, A. C. Yeung, B. H. Johnstone, P. G. Yock and
K. L. March, Circulation, 2005, 112, 150–157.
5 Y. L. Tang, Y. Tang, Y. C. Zhang, K. Qian, L. Shen and
M. I. Phillips, J. Am. Coll. Cardiol., 2005, 46, 1339–1350.
6 S. H. Li, T. Y. Y. Lai, Z. Sun, M. Han, E. Moriyama, B. Wilson,
S. Fazel, R. D. Weisel, T. Yau, J. C. Wu and R. K. Li, J. Thorac.
Cardiovasc. Surg., 2009, 137, 1225–1233.This journal is © The Royal Society of Chemistry 20197 J. M. Karp and G. S. Leng Teo, Cell Stem Cell, 2009, 4, 206–
216.
8 D. Feyen, R. Gaetani, J. Deddens, D. van Keulen, C. van
Opbergen, M. Poldervaart, J. Alblas, S. Chamuleau, L. van
Laake, P. Doevendans and J. Sluijter, Adv. Healthcare
Mater., 2016, 5, 1071–1079.
9 T. Dvir, A. Kedem, E. Ruvinov, O. Levy, I. Freeman, N. Landa,
R. Holbova, M. S. Feinberg, S. Dror, Y. Etzion, J. Leor and
S. Cohen, Proc. Natl. Acad. Sci. U. S. A., 2009, 106, 14990–
14995.
10 J. M. Singelyn, P. Sundaramurthy, T. D. Johnson, P. J. Schup-
Magoﬃn, D. P. Hu, D. M. Faulk, J. Wang, K. M. Mayle,
K. Bartels, M. Salvatore, A. M. Kinsey, A. N. Demaria,
N. Dib and K. L. Christman, J. Am. Coll. Cardiol., 2012, 59,
751–763.
11 R. Ravichandran, J. R. Venugopal, S. Sundarrajan,
S. Mukherjee, R. Sridhar and S. Ramakrishna,
Nanotechnology, 2012, 23, 385102.
12 M. Montgomery, S. Ahadian, L. Davenport Huyer, M. Lo Rito,
R. A. Civitarese, R. D. Vanderlaan, J. Wu, L. A. Reis,
A. Momen, S. Akbari, A. Pahnke, R. K. Li, C. A. Caldarone
and M. Radisic, Nat. Mater., 2017, 16, 1038–1046.
13 F. Wang and J. Guan Jianjun, Adv. Drug Delivery Rev., 2010,
62, 784–797.
14 I. K. Ko, T. J. Kean and J. E. Dennis, Biomaterials, 2009, 30,
3702–3710.
15 K. Cheng, D. Shen, M. T. Hensley, R. Middleton, B. Sun,
W. Liu, G. De Couto and E. Marba´n, Nat. Commun., 2014,
5, 4880.
16 C. Y. Lo, B. R. Weil, B. A. Palka, A. Momeni, J. M. Canty and
S. Neelamegham, Biomaterials, 2016, 74, 19–30.
17 Y. Teramura, Y. Kaneda, T. Totani and H. Iwata,
Biomaterials, 2008, 29, 1345–1355.
18 Y. He, Y. Guo, Y. Xia, Y. Guo, R. Wang, F. Zhang, L. Guo,
Y. Liu, T. Yin, C. Gao, E. Gao, C. Li, S. Wang, L. Zhang,
W. Yan and L. Tao, Am. J. Physiol.: Heart Circ. Physiol.,
2018, 316, H233–H244.
19 Z. Li, D. Shen, S. Hu, T. Su, K. Huang, F. Liu, L. Hou and
K. Cheng, ACS Nano, 2018, 12, 12193–12200.
20 T. J. Antes, R. C. Middleton, K. M. Luther, T. Ijichi, K. A. Peck,
W. J. Liu, J. Valle, A. K. Echavez and E. Marba´n, J.
Nanobiotechnol., 2018, 16, 1–15.
21 A. Vandergriﬀ, K. Huang, D. Shen, S. Hu, M. T. Hensley,
T. G. Caranasos, L. Qian and K. Cheng, Theranostics, 2018,
8, 1869–1878.
22 T. J. Kean, P. Lin, A. I. Caplan and J. E. Dennis, Stem Cells
Int., 2013, 2013, 732742.
23 P. Klemm and M. A. Schembri, Int. J. Med. Microbiol., 2000,
290, 27–35.
24 B. Henderson, S. Nair, J. Pallas and M. A. Williams, FEMS
Microbiol. Rev., 2011, 35, 147–200.
25 R. McNab, A. R. Holmes, J. M. Clarke, G. W. Tannock and
H. F. Jenkinson, Infect. Immun., 1996, 64, 4204–4210.
26 N. S. Jakubovics, J. L. Brittan, L. C. Dutton and
H. F. Jenkinson, Microbiology, 2009, 155, 3572–3580.
27 M. H. Konstandin, H. Toko, G. M. Gastelum, P. Quijada,
A. De La Torre, M. Quintana, B. Collins, S. Din,Chem. Sci., 2019, 10, 7610–7618 | 7617
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
3 
Ju
ly
 2
01
9.
 D
ow
nl
oa
de
d 
on
 9
/1
2/
20
19
 2
:3
5:
49
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineD. Avitabile, M. Vo¨lkers, N. Gude, R. Fa¨ssler and
M. A. Sussman, Circ. Res., 2013, 113, 115–125.
28 A. Van Dijk, H. W. M. Niessen, W. Ursem, J. W. R. Twisk,
F. C. Visser and F. J. VanMilligen, Cell Tissue Res., 2008,
332, 289–298.
29 C. R. Back, M. N. Sztukowska, M. Till, R. J. Lamont,
H. F. Jenkinson, A. H. Nobbs and P. R. Race, J. Biol. Chem.,
2017, 292, 1538–1549.
30 J. P. K. Armstrong, R. Shakur, J. P. Horne, S. C. Dickinson,
C. T. Armstrong, K. Lau, J. Kadiwala, R. Lowe, A. Seddon,
S. Mann, J. L. R. Anderson, A. W. Perriman and
A. P. Hollander, Nat. Commun., 2015, 6, 7405.
31 A. P. S. Brogan, R. B. Sessions, A. W. Perriman and S. Mann,
J. Am. Chem. Soc., 2014, 136, 16824–16831.
32 M. S. Lawrence, K. J. Phillips and D. R. Liu, J. Am. Chem. Soc.,
2007, 129, 10110–10112.7618 | Chem. Sci., 2019, 10, 7610–761833 D. B. Thompson, J. J. Cronican and D. R. Liu, in Methods in
Enzymology, Elsevier Inc., 1st edn, 2012, vol. 503, pp. 293–
319.
34 Y. Krishnan, H. A. Rees, C. P. Rossitto, S.-E. Kim, H.-H.
K. Hung, E. H. Frank, B. D. Olsen, D. R. Liu,
P. T. Hammond and A. J. Grodzinsky, Biomaterials, 2018,
183, 218–233.
35 A. M. Malek, S. L. Alper and S. Izumo, JAMA, J. Am. Med.
Assoc., 1999, 282, 2035–2042.
36 R. H. Lee, A. A. Pulin, M. J. Seo, D. J. Kota, J. Ylostalo,
B. L. Larson, L. Semprun-Prieto, P. Delafontaine and
D. J. Prockop, Cell Stem Cell, 2009, 5, 54–63.
37 H. Wang, X. Liang, Z. P. Xu, D. H. G. Crawford, X. Liu and
M. S. Roberts, Sci. Rep., 2016, 1–12.
38 D. A. Lerman, A. Nasri, U. Kiddy Levente and P. Bruno, Eur
Cardiol., 2016, 11, 43–48.This journal is © The Royal Society of Chemistry 2019
